Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-14. Numbers and descriptions here follow the published literature rather than marketing material.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Collagen α-1 (XXIII) chain is a protein encoded by COL23A1 gene, which is located on chromosome 5q35 in humans, and on chromosome 11B1+2 in mice. The location of this gene was discovered by genomic sequence analysis. Collagen XXIII is a type II transmembrane protein and the fourth in the subfamily of non-fibrillar transmembranous collagens. This kind of collagens have a single pass hydrophobic transmembrane domain. The molecule of collagen XXIII can be found either in membrane-bond form or in shed form. Type XXIII collagen is expressed in both adult tissues and developing organs. It can be found in the epidermis and other epithelia such as those in tongue, gut and lung, but also in the brain, the kidney and the cornea. It has been shown that in prostate collagen XXIII expression is associated with tumor progression. The functions of collagen XXIII are still unknown, although it is believed that they could be similar to other transmembrane proteins, such as collagen XIII.
=== Mechanism of action === Lisinopril is an ACE inhibitor, meaning it blocks the actions of angiotensin-converting enzyme (ACE) in the renin–angiotensin–aldosterone system (RAAS), preventing angiotensin I from being converted to angiotensin II. Angiotensin II is a potent direct vasoconstrictor and a stimulator of aldosterone release. Reduction in the amount of angiotensin II results in relaxation of the arterioles. Reduction in the amount of angiotensin II also reduces the release of aldosterone from the adrenal cortex, which allows the kidney to excrete sodium along with water into the urine and increases the retention of potassium ions. Specifically, this process occurs in the peritubular capillaries of the kidneys in response to a change in Starling forces. The inhibition of the RAAS system causes an overall decrease in blood pressure.
=== Legal status === Kostaive was approved for medical use in Japan in November 2023. In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kostaive, a vaccine intended for the prevention of COVID-19 in adults. The applicant for this medicinal product is Arcturus Therapeutics Europe B.V. Zapomeran was authorized for medical use in the European Union in February 2025, and in the UK in January 2026.
==== Codon models ==== Codon models describe the evolution of protein-coding nucleic acid sequences. The simplest codon model, MG, estimates one parameter: nonsynonymous/synonymous mutation ratio. The more complex GY also estimates transition/transversion rate ratios. Both of these are mechanistic models. They can be expanded by the addition of rate parameters. Empirical codon models directly describe the odds of one non-stop codon (61 in the standard code) being replaced by another, making them similar to amino acid exchangability matrices. By their construction, they are tied to the genetic code found in the data used to construct them. They can also be combined with a mechanistic model by multiplying the two estimated rates, adding back the ability to adapt to the data being processed.
Le Havre belongs to the Paris Basin which was formed in the Mesozoic period. The Paris Basin consists of sedimentary rocks. The commune of Le Havre consists of two areas separated by a natural cliff edge: one part in the lower part of the town to the south including the harbour, the city centre and the suburbs. It was built on former marshland and mudflats that were drained in the 16th century. The soil consists of several metres of alluvium or silt deposited by the Seine. The city centre was rebuilt after the Second World War using a metre of flattened rubble as a foundation. The upper town to the north, is part of the cauchois plateau: the neighbourhood of Dollemard is its highest point (between 90 and 115 metres (295 and 377 feet) above sea level). The plateau is covered with a layer of flinty clay and a fertile silt. The bedrock consists of a large thickness of chalk measuring up to 200 m (656 ft) deep. Because of the slope the coast is affected by the risk of landslides.
Sources: en.wikipedia.org
The two substrates of this enzyme are precorrin-2 and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are sirohydrochlorin, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is precorrin-2:NAD+ oxidoreductase. Other names in common use include Met8p, SirC, and CysG. This enzyme is part of the biosynthetic pathway to cobalamin (vitamin B12) in anaerobic bacteria and to Cofactor F430.
) and a high filling factor, resulting in a strong coupling between the probe coil and the sample. The phenomenon is also impacted by the concentration of the nuclei within the sample and their magnetic moments, which can intensify the effects of radiation damping. The strength of the magnetic field is inversely proportional to the lifetime of RD. The impact of radiation damping on NMR signals is multifaceted. It can accelerate the decay of the NMR signal faster than intrinsic relaxation processes would suggest. This acceleration can complicate the interpretation of NMR spectra by causing broadening of spectral lines, distorting multiplet structures, and introducing artifacts, especially in high-resolution NMR scenarios. Such effects make it challenging to obtain clear and accurate data without considering the influence of radiation damping. To mitigate these effects, various strategies are employed in NMR spectroscopy. These methods majorly stem from hardware or software. Hardware modifications including RF feed-circuit and Q-factor switches reduce the feedback loop between the sample magnetization and the electromagnetic field induced by the coil and function successfully. Other approaches such as designing selective pulse sequences also effectively manage the fields induced by radiation damping. These approaches aim to control and limit the disruptive effects of radiation damping during NMR experiments and all approaches are successful in eliminating RD to a fairly large extent.
== Author == Lisa Sanders was born on July 24, 1956, in South Carolina. Sanders grew up loving the idea of mystery and became fond of Arthur Conan Doyle's fictional character, detective Sherlock Holmes. Sanders went to the College of William & Mary where she majored in English. After her graduation in 1979, she was hired by ABC News as a journalist. During her 10-year career as a journalist, Sanders won an Emmy award for her reporting of Hurricane Hugo. She was repeatedly drawn to stories that focused around mysteries and medicine. After about 10 years of reporting, Sanders decided to pursue a career within the medical field. She was accepted into the post-baccalaureate pre-medical program at Columbia University. After completing her pre-medical requirements, she was accepted into Yale Medical School. She completed her residency at Yale and became her class’s chief resident. Sanders became an attending internal medicine physician for the Yale-New Haven Hospital. As her new career progressed, she joined Yale’s Department of Internal Medicine while also teaching primary care at the school of medicine. In 2002, a friend of hers working at The New York Times sparked a conversation about what doctors could provide in a literature perspective. After more discussion, Sanders started writing a column for The New York Times called Diagnosis. The column would highlight medical mysteries that she would encounter with her own patients and those of her colleagues. She described the cases as mysteries, revealing the diagnosis in the following week's column.
Also that same day, three civilians were injured in Pakistani drone strikes in Paktika Province and two civilians were injured in a drone strike in Khost Province, and two civilians were killed and 25 wounded in more than 155 mortar and artillery strikes in Kunar Province. On 3 April, Taliban officials said that two civilians were killed and 25 others were injured as a result of Pakistani forces cross-border strikes in parts of Eastern Afghanistan. On the same day, Pakistani Taliban carried out a vehicle borne suicide bombing in the vicinity of a police station, killing five civilians and injuring police personnel and civilians. 37 insurgents were killed and more than 80 wounded, in a failed infiltration attempt across the border in North Waziristan. On 5 April, Taliban officials stated that between 22 February and 3 April, at least 761 civilians were killed and 626 others injured in attacks attributed to Pakistani forces. Taliban officials did not clarify whether any Taliban members were included among the casualties or what specific targets were struck. According to the officials, Pakistani forces fired approximately 15,000 mortar rounds and rockets into Afghanistan during this period. The reported affected regions included Kabul, Kandahar, Paktia, Paktika, Nangarhar, Khost, Kunar, Laghman, and Nuristan. In addition to human casualties, Taliban authorities reported significant damage to civilian infrastructure, including around 1,140 homes, 13 religious schools, 13 public schools, three health centers, 34 mosques, and 42 vehicles.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.